Lyell Immunopharma, Inc. LYEL
9.85
(0.27)
(2.67%)
as of 25 Sep
- Market cap
- $248.0M
- P/E
- 0.0×
Follow LYEL
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12,157.93 | 14,155.89 | 14,614.52 | 7,235.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.68) | (11.40) | (16.31) | (10.38) | |
P/B ratio |
1.40 | 1.60 | 2.12 | 0.90 | |
Price to Tangible BV |
1.40 | 1.60 | 2.12 | 0.90 | |
EV/Sales |
4,598.60 | 5,961.60 | 7,747.29 | (559.80) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.07 | |
EV/Operating CF |
(0.93) | (1.38) | (1.86) | 0.14 | |
EV/FCF |
(0.71) | (1.05) | (1.45) | 0.12 | |
Quick Ratio |
5.12 | 6.88 | 5.00 | 10.03 | |
Current Ratio |
5.36 | 7.23 | 5.28 | 10.30 | |
Net Debt/EBITDA |
4.44 | 5.93 | 1.96 | 8.95 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 1.59 | 0.23 | 0.74 | |
Capex/Depreciation |
(0.18) | (0.06) | (31.02) | 0.13 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
988,100.00% | 1,830,200.00% | 869,983.33% | 187,813.33% | |
Selling, General and Administrative Expense of Revenue |
239,400.00% | 477,750.00% | 176,933.33% | 71,246.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
113,300.00% | 214,750.00% | 426,150.00% | 34,880.00% | |
Graham Net Nets |
0.41 | 0.43 | 0.32 | 0.84 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(91.32%) | (68.79%) | (52.96%) | (141.75%) | |
Free Cash Flow Yield |
(53.27%) | (39.95%) | (36.44%) | (66.27%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.45) | (1.76) | (1.89) | (1.56) | |
Capex per Share |
(0.01) | 0.00 | (2.43) | 0.01 | |
Free Cash Flow per Share |
(1.46) | (1.76) | (4.31) | (1.55) | |
Cash per Share |
8.74 | 11.61 | 14.46 | 17.50 | |
Shareholders Equity per Share |
10.01 | 12.51 | 14.52 | 18.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.01 | 12.51 | 14.52 | 18.02 | |
Free Cash Flow |
(34.17) | (38.60) | (73.73) | (28.38) | |
Working Capital |
173.67 | 230.36 | 211.53 | 296.32 | |
Capital Expenditures |
(0.25) | (0.09) | (41.47) | 0.20 | |
Net Current Asset Value |
136.20 | 190.34 | 169.09 | 249.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.07 | |
Capex to Sales |
62.75 | 44.50 | 6,912.50 | (13.40) | |
Net Profit Margin |
(1,118,875.00%) | (1,207,650.00%) | (2,345,383.33%) | (258,973.33%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.63 | 4.60 | 4.13 | 3.08 | |
Average Assets |
348.30 | 390.21 | 415.46 | 513.59 | |
Average Common Equity |
266.37 | 305.09 | 315.51 | 429.91 |
Columns are period end dates